Manatt’s Ian Spatz, a senior advisor with our Manatt Health team, was interviewed on a PharmaVoice podcast about the effectiveness of the potential drug price transparency requirement.
The Trump administration’s Center for Medicare and Medicaid Services proposed a requirement for drug makers to disclose drug prices in television advertisements. According to the publication, the administration claimed that this proposed requirement would lower drug prices and help consumers make smarter decisions.
“Frankly, they provide very little rationale for how this idea would actually lead to lower drug prices or lower drug price increases. And what rationale they provide just seems quite weak to me,” said Spatz.
Read the article here.